SCHEMBL13877940

SCHEMBL13877940

C[C@@]12CC(=O)C[C@@](C)(C1)[C@@H](O)[C@H]2O

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.33
PTPN1 P18031 1/20 0.31
MAPT P10636 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13877939 0.72 GAA (0.30) GAA
SCHEMBL3658102 0.67 LMNA (0.31) LMNAPTPN1MAPT
SCHEMBL638075 0.65 MAPT (0.36) LMNAMAPTGAA
SCHEMBL20797183 0.65
SCHEMBL14016355 0.64 SMN1; SMN2 (0.38) LMNAMAPT
SCHEMBL4859696 0.64 KDM4E (0.39) LMNAMAPT
SCHEMBL2691041 0.64
SCHEMBL2706623 0.64 SMN1; SMN2 (0.38) LMNAMAPT
SCHEMBL688787 0.63 ALDH1A1 (0.30) MAPT
SCHEMBL1665247 0.62 ALDH1A1 (0.32) LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8497376-B2 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-30 US disclosed
US-20090105296-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105296-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES LMNA 3217/4885PTPN1 391/4885MAPT 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.